Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
Phase 4
Recruiting
- Conditions
- HypertensionLeft Ventricular Hypertrophy
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT05593055
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT05593653
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Next Generation Ingestible Sensors for Medication Adherence Measurement
Phase 3
Active, not recruiting
- Conditions
- Pre-Exposure ProphylaxisHIV InfectionAntiretroviral TherapyAdherence, TreatmentAdherence, Medication
- Interventions
- Device: Next-generation Reader and ID-Cap System
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT05592613
- Locations
- 🇺🇸
Fenway Health, Boston, Massachusetts, United States
Acetazolamide on REM OSA
Phase 1
Active, not recruiting
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05589792
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Withdrawn
- Conditions
- Reflux Disease, Gastro-EsophagealMotility DisorderGastroesophageal Reflux Disease (GERD)Laryngopharyngeal Reflux (LPR)
- Interventions
- Device: Transoral Incisionless Fundoplication
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Brigham and Women's Hospital
- Registration Number
- NCT05579587
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Replication of the SEPRA Diabetes Trial in Healthcare Claims Data
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: New use of semaglutide injectionDrug: New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 2316
- Registration Number
- NCT05577728
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Personalizing Preprocedural Sedation for Regional Anesthesia
Early Phase 1
Completed
- Conditions
- Catastrophizing Pain
- Interventions
- Behavioral: Educational Reassurance
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT05579509
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
Phase 2
Recruiting
- Conditions
- Asthma, Aspirin-InducedAspirin-Sensitive Asthma With Nasal PolypsNasal PolypsAspirin-Exacerbated Respiratory Disease
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT05575037
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Anti-Platelets in Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- EmphysemaCOPDEmphysema or COPD
- Interventions
- Combination Product: dual anti-platelet therapyDrug: Placebo
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT05567562
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Monounsaturated Fatty Acid Supplementation for Overweight and Obese Individuals with Prediabetes
Not Applicable
Active, not recruiting
- Conditions
- OverweightObesityPreDiabetesInsulin Resistance
- Interventions
- Other: PlaceboDietary Supplement: Palmitoleic acid
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05560971
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath